

CHIO3 Trial

CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)

Martin LW, Wang X, Kozono D, et al. CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46). Lung Cancer. 2026;215:109374. doi: 10.1016/j.lungcan.2026.109374




ANNENBERG CENTER FOR HEALTH SCIENCES

AT EISENHOWER

Imparting knowledge. Improving patient care.

CHIO3 Trial: Efficacy (Overall Population)



CHIO3: Safety Analysis

Adverse Events (Grade 1-5)	During Neoadjuvant Phase (N=37)	During Adjuvant Phase (n=20)
Anemia	40%	15%
White blood cell decreased	24%	-
Lymphocyte count decreased	19%	20%
Fatigue	57%	15%
Diarrhea	19%	-
Mucositis	19%	-
Rash maculo-papular	-	30%
Thyroid stimulating hormone increased	-	25%
Hypoglycemia	-	15%

